U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849713) titled 'Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients with CLL or SLL' on Feb. 12.
Brief Summary: The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Study Start Date: July 28, 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma (SLL)
Intervention:
DRUG: Zanubrutinib
Bruton's Tyrosine Kinase (BTK) inhibitor
DRUG: Sonrotoclax
B-cell lymphoma 2 (BCL2) protein inhibitor
DRUG: Obinutu...